Arkadios Wealth Advisors Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Arkadios Wealth Advisors lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,510 shares of the biopharmaceutical company's stock after selling 10,473 shares during the period. Arkadios Wealth Advisors' holdings in Gilead Sciences were worth $2,172,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares during the period. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences in the fourth quarter worth approximately $29,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Quarry LP bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $43,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the company's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company's stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.19 during trading on Friday, hitting $91.84. The stock had a trading volume of 6,852,085 shares, compared to its average volume of 5,370,915. The firm has a market cap of $114.46 billion, a price-to-earnings ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The business's 50-day moving average is $91.75 and its 200 day moving average is $84.08. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.29 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences's payout ratio is currently 3,422.22%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GILD. Leerink Partnrs upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Robert W. Baird upped their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. BMO Capital Markets boosted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.